Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA, USA.
William R Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California-Davis, Davis, CA, USA.
J Feline Med Surg. 2021 Jun;23(6):519-525. doi: 10.1177/1098612X20961046. Epub 2020 Oct 6.
The aim of this study was to determine famciclovir content (strength) in compounded formulations and to determine if potency changed over time.
Four concentrations of oral oil suspension in three distinct flavors, three concentrations of oral paste, three chew treats and 62.5 mg tablets from one compounding pharmacy were evaluated for famciclovir content. Specific sample preparation procedures were used for each drug formulation prior to determination of famciclovir content through mass spectrometry tandem liquid chromatography. Analysis was performed on arrival from the compounder and on days 7, 14, 28, 56 and 120. Samples were run in triplicate and concentration determined by comparison with a standard curve. Content was considered appropriate if within 90-110% of the labeled concentration.
On arrival from the compounding pharmacy, 5/12 oral oil suspensions of varying concentrations were <90% of the labeled concentration and 3/3 oral pastes were >110%. Famciclovir content in oil suspensions ranged from 72% to 118% of the label value while oral pastes ranged from 95% to 202% of the label concentration over the 120 study days, and all concentrations varied in an unpredictable fashion. Tablets contained 90-110% of the labeled value throughout the study period. Chew treats could not be successfully analyzed.
This study found substantial variation in famciclovir content in the compounded products evaluated, which, in turn, raises concerns that substandard dosing could result in lack of efficacy or a failed treatment trial. Drug toxicity might also be encountered. Veterinarians must be aware that while compounded medications can improve compliance, they might not deliver the drug dose expected.
本研究旨在确定复方制剂中泛昔洛韦的含量(效力),并确定其效力是否随时间发生变化。
评估了一家复方制剂药房的四种不同浓度的口服油混悬剂(三种不同口味)、三种浓度的口服糊剂、三种咀嚼剂和 62.5mg 片剂中泛昔洛韦的含量。在通过质谱串联液相色谱法测定泛昔洛韦含量之前,针对每种药物制剂采用了特定的样品制备程序。在从复方制剂药房送达时以及第 7、14、28、56 和 120 天进行分析。样品一式三份进行分析,通过与标准曲线比较来确定浓度。如果含量在标签浓度的 90%-110%范围内,则认为是合适的。
从复方制剂药房送达时,5/12 种不同浓度的口服油混悬剂含量<标签浓度的 90%,3/3 种口服糊剂含量>标签浓度的 110%。油混悬剂中的泛昔洛韦含量在标签值的 72%-118%之间,而口服糊剂在 120 天的研究期间,其含量在标签浓度的 95%-202%之间,所有浓度均呈不可预测的变化。片剂在整个研究期间均含有 90%-110%的标签值。咀嚼剂无法成功分析。
本研究发现评估的复方制剂中泛昔洛韦含量存在较大差异,这反过来又引发了人们对剂量不足可能导致疗效不佳或治疗失败的担忧。也可能会遇到药物毒性问题。兽医必须意识到,虽然复方药物可以提高顺应性,但它们可能无法提供预期的药物剂量。